Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
Coskun T, Wu Q, Schloot NC, et al. (2025). The Lancet Diabetes & Endocrinology.
Summary
A body-composition substudy of a phase 2 trial run at 42 US centres, in which adults with type 2 diabetes were randomised to weekly placebo, dulaglutide or one of several retatrutide dose groups for 36 weeks. Total fat mass was measured by DXA. Fat mass fell by roughly a quarter in the higher retatrutide groups versus about 4–5% with placebo and about 3% with dulaglutide, and the proportion of lean mass lost relative to total weight lost was reported as similar to other obesity treatments. Gastrointestinal events were the most common adverse events. Funded by Eli Lilly; all authors are Lilly employees.